新光药业(300519) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 64,675,638.69, a decrease of 7.61% year-over-year[5] - Net profit attributable to shareholders was CNY 13,428,481.93, an increase of 9.40% year-over-year[5] - Net profit excluding non-recurring items was CNY 14,049,350.55, up 17.28% year-over-year[5] - Total operating revenue for the current period was ¥205,618,567.89, a decrease of 4.1% from ¥216,211,460.22 in the previous period[20] - Operating profit increased to ¥55,022,446.12, up 27.0% from ¥43,333,037.11 in the previous period[20] - Net profit margin improved, with total profit amounting to ¥53,571,739.38, an increase of 25.7% compared to ¥42,627,311.11 in the previous period[20] - The net profit for the current period is $45,336,178.34, an increase of 19.9% compared to $37,782,359.75 in the previous period[21] - The total comprehensive income for the current period is $45,416,541.70, up from $37,798,974.14, reflecting a growth of 20.5%[21] - The basic and diluted earnings per share are both $0.28, compared to $0.24 in the previous period, representing a 16.7% increase[21] Cash Flow - Cash flow from operating activities was CNY 50,588,056.01, an increase of 42.97% year-over-year[9] - Cash flow from operating activities generated a net amount of $50,588,056.01, an increase from $35,382,757.18, marking a growth of 43%[23] - Cash flow from investing activities resulted in a net outflow of $215,373,023.93, worsening from a net outflow of $90,716,421.32 in the previous period[23] - Cash flow from financing activities showed a net outflow of $48,000,000.00, compared to a net outflow of $64,000,000.00 in the previous period, indicating an improvement of 25%[24] - The ending cash and cash equivalents balance is $290,631,157.54, down from $424,612,128.76, reflecting a decrease of 31.5%[24] - The company received $12,460,655.66 in other cash related to operating activities, significantly up from $5,841,377.75 in the previous period, a growth of 113.8%[23] Assets and Liabilities - Total assets at the end of the period were CNY 893,406,144.02, down 1.80% from the previous year[5] - Cash and cash equivalents decreased to ¥290,631,157.54 from ¥503,416,125.46, a decline of 42.3%[18] - Total current assets amounted to ¥767,648,466.09, slightly down from ¥774,713,254.45, a decrease of 0.8%[18] - Total liabilities decreased to ¥65,457,772.72 from ¥79,249,505.77, a reduction of 17.4%[19] - Total equity attributable to shareholders was ¥827,948,371.30, down from ¥830,531,829.60, a decrease of 0.3%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,602[13] - The largest shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[13] - The second-largest shareholder, Shengzhou Hefeng Investment Co., Ltd., holds 15.74% of the shares, totaling 25,181,000 shares[13] - The shareholder Qian Haishao holds a total of 2,089,000 shares, accounting for 1.31% of the total shares[13] - The company has no preferred shareholders or related changes in restricted shares during the reporting period[15] - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing[14] Corporate Governance - The company has decided to abolish the supervisory board, transferring its powers to the audit committee of the board of directors[16] - The company has revised its articles of association and various management systems, which were approved at the shareholders' meeting on September 12, 2025[16] - The company has not disclosed any related party relationships among shareholders, except for Wang Yuejun and Shengzhou Hefeng Investment Co., Ltd.[14] Expenses - Financial expenses increased by 155.77% to CNY -11,030,658.39 due to higher bank deposit interest income[9] - Research and development expenses increased to ¥10,041,721.84, up from ¥9,618,279.84, a rise of 4.4%[20] - The company reported a tax expense of $8,235,561.04, compared to $4,844,951.36 in the previous period, which is an increase of 70.5%[21] - Other comprehensive income after tax attributable to the parent company is $80,363.36, a significant increase from $16,614.39, representing a growth of 383.5%[21] Other Financial Metrics - The company reported a significant increase in other receivables by 398.23% to CNY 190,430.90, mainly due to overpayment of land use fees[8] - Investment activities generated a net cash outflow of CNY -215,373,023.93, an increase of 137.41% year-over-year due to increased purchases of financial products[11] - The net increase in cash and cash equivalents was CNY -212,784,967.92, a decrease of 78.31% year-over-year[11]